3 completed, 3 withdrawn, 2 active not recruiting, 2 recruiting. 7 Phase 2, 6 Phase 1, 1 Not applicable.
Follow Unresectable Renal Cell Carcinoma: new trials by email Literature Review of Unresectable Renal Cell Carcinoma trials Research Report on Unresectable Renal Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma Aldesleukin, Biopsy, Biospecimen Collection - Locally Advanced Cervical Carcinoma, Locally Advanced Colorectal Carcinoma | Phase 1 | Withdrawn | City of Hope Medical Center | 2025-12-05 | 2025-12-24 | |
| Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC) Time restricted eating (TRE) - Metastatic Head-and-neck Squamous-cell Carcinoma, Unresectable Renal Cell Carcinoma | Not applicable | Withdrawn | Duke University | 2025-11-01 | 2025-12-19 | |
| Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial Avelumab, Axitinib, Biospecimen Collection - Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 | Phase 2 | Recruiting | NRG Oncology | 240 | 2023-02-01 | 2026-09-18 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer Cabozantinib S-malate, Clostridium butyricum CBM 588 Probiotic Strain, Nivolumab - Advanced Clear Cell Renal Cell Carcinoma, Advanced Papillary Renal Cell Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 31 | 2021-11-01 | 2026-03-05 |
| Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer Pamiparib, Temozolomide - Clear Cell Papillary Renal Neoplasm, Collecting Duct Carcinoma | Phase 2 | Withdrawn | Jonsson Comprehensive Cancer Center | 2021-10-18 | 2023-05-17 | |
| Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer Talazoparib, Axitinib - Kidney Cancer, Renal Cell Carcinoma | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 23 | 2020-04-06 | 2026-10-06 |
| CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer Clostridium butyricum CBM 588 Probiotic Strain, Ipilimumab, Nivolumab - Advanced Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma | Phase 1 | Completed | City of Hope Medical Center | 30 | 2019-05-14 | 2024-07-03 |
| A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) Axitinib, Nivolumab - Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 15 | 2019-01-08 | 2026-10-22 |
| Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery Ascorbic Acid, Pazopanib Hydrochloride - Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 5 | 2018-02-16 | 2022-03-31 |
| Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 152 | 2016-07-25 | 2025-01-13 |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies Capecitabine, Carboplatin, Cyclophosphamide - Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8 | Phase 1 | Terminated | M.D. Anderson Cancer Center | 221 | 2015-06-26 | 2025-06-04 |
Carcinoma, Renal Cell (12) · Melanoma (3) · Neoplasm Metastasis (3) · Carcinoma, Non-Small-Cell Lung (2) · Clear-cell metastatic renal cell carcinoma (2) · Lung Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Triple Negative Breast Neoplasms (2) · Uterine Cervical Neoplasms (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Lobular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Transitional Cell (1) · Carcinosarcoma (1) · Colorectal Neoplasms (1)
Adenocarcinoma (12) · Carcinoma (12) · Female Urogenital Diseases (12) · Female Urogenital Diseases and Pregnancy Complications (12) · Kidney Diseases (12) · Male Urogenital Diseases (12) · Neoplasms (12) · Neoplasms by Histologic Type (12) · Neoplasms by Site (12) · Neoplasms, Glandular and Epithelial (12) · Urogenital Diseases (12) · Urogenital Neoplasms (12) · Urologic Diseases (12) · Urologic Neoplasms (12) · Kidney Neoplasms (11)
Nivolumab (5) · Specimen Handling (4) · Axitinib (3) · CTLA-4 Antigen (3) · Cyclophosphamide (3) · Ipilimumab (3) · Magnetic Resonance Spectroscopy (3) · cabozantinib (3) · pembrolizumab (3) · Biopsy (2) · 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine (1) · Ascorbic Acid (1) · Capecitabine (1) · Carboplatin (1) · Colony-Stimulating Factors (1)
City of Hope Medical Center (3) · National Cancer Institute (NCI) (2) · Academic and Community Cancer Research United (1) · Duke University (1) · Jonsson Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Memorial Sloan Kettering Cancer Center (1) · NRG Oncology (1)
United States (10) · Canada (2) · Australia (1) · Ireland (1) · Puerto Rico (1)
Sumanta K Pal (3) · Aung Naing, MD (1) · Brian Shuch, MD (1) · Daniel George, MD (1) · James I Geller (1) · Lance C Pagliaro (1) · Ritesh Kotecha, MD (1) · Vincent Chung (1) · William A Hall (1) · Yanyan Lou, MD, PhD (1)
PMID 33592176, PMID 33909232, PMID 34562230, PMID 34965890, PMID 35228755, PMID 36464584, PMID 37129197, PMID 37146227, PMID 38942995, PMID 39255440, PMID 39816915, PMID 39945382
P30CA033572 (3), P30CA015083 (1), U10CA180868 (1), U10CA180886 (1), U10CA180888 (1)